SJ-300 is a potent and selective, orally active and brain-penetrat DKK3-LRP1 interaction inhibitor. SJ-300 restores Abeta clearance in AD models. SJ 300 binds to mLRPIV with a Kd of 7.9 µM, inhibits the DKK3 mLRPIV complex with an IC50 of 3.2 µM, and does not disrupt the binding of Abeta to LRP1. SJ 300 rescues cognitive function and ameliorates neuropathology (Abeta plaque reduction ~ 73.3 %) in vivo. SJ 300 can be employed for research in Alzheimers disease[1].
Molekulargewicht:
342.45
CAS Nummer:
[1210357-06-4]
Formel:
C20H27FN4
Target-Kategorie:
Amyloid-beta,LDLR,Wnt
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
